Recombinant Chicken SMAD1

• Cat.No.: SMAD1-4493C
• Product Overview: Recombinant Chicken SMAD1 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Chicken
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: SMAD1 mothers against decapentaplegic homolog 1 [ Gallus gallus (chicken) ]
• Official Symbol: SMAD1
• Gene ID: 395680
• Protein Refseq: NP_001188384
• UniProt ID: Q56IA0

Reviews

06/08/2022

Whether I am investigating enzymatic activity, studying protein-protein interactions, or testing its role in signaling pathways, the SMAD1 protein consistently performs exceptionally well.

08/08/2021

This versatility allows me to explore different aspects of my research with confidence and accuracy.

05/02/2018

The SMAD1 protein's excellent functionality makes it highly suitable for various trial applications.

Q&As

What technologies are commonly used to study the expression and activity of SMAD1 in clinical research?

Techniques like Western blotting, immunohistochemistry, and qRT-PCR are commonly employed to study SMAD1 expression and activity in clinical research.

How might targeting SMAD1 have implications for anti-cancer therapies?

Modulating SMAD1 activity could be explored as a potential strategy for developing anti-cancer therapies, particularly in cancers where the TGF-β pathway is dysregulated.

Are there any known genetic mutations in the SMAD1 gene associated with human diseases?

Yes, mutations in the SMAD1 gene have been identified in certain individuals with congenital disorders and developmental abnormalities.

How does SMAD1 interact with other proteins in the TGF-β pathway?

SMAD1 forms complexes with other SMAD proteins, transducing signals from TGF-β receptors to the nucleus, where they regulate gene expression.

How can SMAD1 be targeted for therapeutic interventions in bone-related disorders?

Targeting SMAD1 or its downstream effectors in the TGF-β pathway may offer potential therapeutic strategies for bone-related disorders, such as osteoporosis.